Experimental Therapeutics and Molecular Pathophysiology (ETMP) Program

The mission of the Experimental Therapeutics and Molecular Pathophysiology Program (ETP) is to conduct clinical (proof of concept studies) and translational (targeted biomarkers of response) in Psychiatric Disorders. The ETP focuses on testing new or repurposed, experimental agents for psychiatric disorders in Proof of Concept clinical trials. In addition, the ETP evaluates target engagement and biomarkers of response of these drugs using imaging tools and peripheral biomarkers. This approach uses biomarkers to predict response to medications, allowing a better understanding of the brain mechanisms involved in therapeutic response in the context of personalized medicine.

Directed by Rodrigo Machado-Vieira, MD, PhD MSc, the ETP uses a wide range of technologies including brain imaging, biochemical, molecular and genetic studies to identify biological signatures of therapeutic response in human studies. Dimensional approaches are also used in research to provide new insights in anhedonia, suicide and other RDoC dimensions. Dr. Machado-Vieira has active collaborations with other academic institutions, the National Institutes of Health (NIH) and Pharma. The program is currently looking for outstanding Postdoctoral Fellows and Research Assistants.

Research opportunities at the Experimental Therapeutics and Molecular Pathophysiology Program (ETP)


ETP Clinical trials currently recruiting patients